Project Grant R21TW011720

This federal Cooperative Agreement award of $1,242,348 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to investigate the potential role of cyanobacteria and cyanotoxins in the development of liver cancer. The primary awardee, the University of Hawaii, will conduct a nested case-control study across four U.S. cohorts to evaluate the association between cyanobacteria, cyanotoxin exposure, and the risk of hepatocellular carcinoma...

This $580,238 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund research to develop a novel blood-based screening approach to detect early-stage hepatocellular carcinoma (HCC) in Hispanic individuals with chronic hepatitis B virus (HBV) infection. The Regents of the University of Minnesota, acting through their Office of Sponsored Projects Administration, will lead a multi-national study to evaluate peripheral immune...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $300,000 to expand the Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort study at the University of California, Davis (UC Davis). The goal is to enroll approximately 1,000 participants with liver cirrhosis, with a focus on the Latinx population, and follow them prospectively to investigate the role of the gut-liver axis in hepatocellular...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports an investigation into the role of metabolic stress and reprogramming in the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC), the most common form of liver cancer. The $2,397,277 project, awarded on September 9, 2024, with a completion date of August 31, 2029, is being conducted by the Sanford Burnham Prebys Medical Discovery Institute. The project...

The National Institute of Environmental Health Sciences (NIEHS) awarded a $238,500 Project Grant under the Environmental Health (CFDA 93.113) federal grant program to the Massachusetts Institute of Technology (MIT) for the project "Leveraging Mutational Analysis of Cell-Free DNA to Identify Carcinogenic Exposure and Enable Early Detection of Cancer". The goal is to develop a novel blood-based analytical tool to rapidly detect mutational profiles of environmental toxicants like...

This federal Project Grant award of $872,878, made by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of California, Davis, aims to study the genetic architecture of breast cancer risk among Hispanic/Latina (H/L) populations in Latin America. The key objectives are to: 1) Discover new genetic susceptibility loci and genes associated with breast cancer risk in H/L populations through genome-wide association studies (GWAS) and transcriptome-wide...

The National Alliance For Hispanic Health was awarded a $750,000 Project Grant from the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283) to implement the "LIVERWISE: HEALTHY LIVER, HEALTHY LIFE!" initiative. This 3-year project, running from September 30, 2024 to September 29, 2027, aims to improve liver health outcomes within the Hispanic community by conducting research, surveillance, and community-based interventions....

The Johns Hopkins University received a $632,241 Cooperative Agreement award from the National Cancer Institute (NCI) under the federal Cancer Cause and Prevention Research (CFDA 93.393) program. The funding will support the implementation and evaluation of the "Liver Cancer Comprehensive Control (LC3) Package" - an integrated intervention bundle focused on HBV diagnostic testing, treatment, adult vaccination, and liver disease screening and surveillance - within existing HIV care...

This Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to identify novel natural products that inhibit TEAD palmitoylation for the prevention and interception of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The $334,254 project, with a period of performance from May 2024 to April 2027, will be conducted by the University of Hawaii at Hilo. The research objectives...

This Project Grant award, titled "INFLAMMATION AND HEPATOCELLULAR CARCINOMA: A MULTIOMICS APPROACH TO IMPROVE EARLY DETECTION, CAUSAL INFERENCE, AND LIFESTYLE BASED PREVENTION", is funded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The $165,883 grant, awarded on February 1, 2025, supports research by Dr. Xinyuan (Cindy) Zhang at Brigham & Women's Hospital Inc. to address gaps in understanding hepatocellular carcinoma (HCC) risk...